Which company does tucatinib/tucatinib come from?

Tucatinib/Tucatinib is an anticancer drug used to treat HER2-positive breast cancer. It is marketed as Tukysa and was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, later part of Seattle Genetics). In April 2020, the drug received approval from the U.S. Food and Drug Administration (FDA) as a promising new treatment for metastatic breast cancer, especially for patients who have not responded well to other chemotherapy regimens.

Tucatinib is a tyrosine kinase inhibitor (TKI) that acts on the HER2 protein. By inhibiting the HER2 protein, tucatinib limits the growth of cancer cells. It can be used in combination with trastuzumab and capecitabine to treat patients with locally advanced or metastatic HER2-positive breast cancer, even those with brain metastases. These patients may have previously received treatments such as trastuzumab, pertuzumab, and T-DM1. The recommended dose of tucatinib is 300 mg taken orally daily in two divided doses. Patients should continue treatment with tucatinib until disease progression or intolerable toxicity occurs.

Clinical trial results of tucatinib show that the combination of tucatinib can significantly prolong patient survival compared with trastuzumab and capecitabine alone. In addition, tucatinib also shows good efficacy in the treatment of brain metastases from HER2-positive breast cancer. This is an important breakthrough for patients whose disease has progressed previously on other treatments.

Although tucatinib has achieved positive results in the treatment of HER2-positive breast cancer, patients still need to pay close attention to possible adverse reactions while using the drug. Some common side effects include diarrhea, vomiting, fatigue, and rash. If patients experience these symptoms, they should inform their doctor in time and make adjustments or rest according to the doctor's advice.